Clinical and Scientific Evidence for MammaPrint + BluePrint

Evidence

SABCS 2019: Chinese Patient Clinical Data

AUTHORS: Ava Kwong, Sarah Untch, Heather M. Kling, Christine Finn, William Audeh, Vivian Shin, Sherene Ishtihar, Margaret Chen DESCRIPTION: Different MammaPrint and BluePrint molecular profiles and clinical-pathological features of early stage breast cancer in Chinese patients in the United States and Hong Kong Breast cancer rates among Asian women are Read More

SABCS 2019: FLEX African American Clinical Data

AUTHORS: Raquel Nunes, Dipali Sharma, Lisa E. Blumencranz, Heather M. Kling, Sahra Uygun, Andrea Menicucci, Amy Truitt, Sarah Untch, Jennifer A. Crozier, William Audeh DESCRIPTION: Racial disparities in breast cancer: identifying predisposing clinical and molecular features associated with African American patients Breast cancer (BC) mortality is higher in African-American women Read More

SABCS 2019: PROMIS Clinical Risk

AUTHORS: Michaela Tsai, Hatem Soliman, Shelly Lo, Rubina Qamar, Raye Budway, Ellis Levine, Pat Whitworth, Blanche Mavromatis, Robin Zon, Sarah Untch1, Lisa Blumencranz, Joseph McKelley, William Audeh, PROMIS Investigators Group DESCRIPTION: Treatment recommendations in ER+ patients ≤ 50 years: comparison of the 21-gene assay and 70-gene signature in the PROMIS Read More

ESMO Sept 30 Successful launch of the MammaPrint and BluePrint NGS

AUTHORS: Leonie JMJ Delahaye, Anke T Witteveen, Mireille HJ Snel1, Tyson Cavness, Bob Chan, Lorenza Mittempergher, Annuska M Glas DESCRIPTION: Successful launch of the MammaPrint and BluePrint NGS kit at decentralized sites Centralized MammaPrint (MP) and BluePrint (BP) microarray-based genomic tests on FFPE RNA were successfully translated to a targeted Read More

ESMO Sept 29 Unravelling the biological characteristics of MammaPrint

AUTHORS Rajith Bhaskaran, Christian J Griffioen, Diedrik Wehkamp, Lorenza Mittempergher and Annuska M Glas DESCRIPTION: Unravelling the biological characteristics of MammaPrint extreme risk subgroups MammaPrint®(MP) is a 70-gene based prognostic assay that stratifies early-stage breast cancer patients into low and high-risk of relapse. Recently, further stratification of the 70-gene risk Read More

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.

PUBLICATION: Transl Oncol. 2019 Sep 9;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. AUTHORS: Slembrouck L., Darrigues L., Laurent C., Mittempergher L., Delahaye L.J., Vanden Bempt I., Vander Borght S., Vliegen L., Sintubin P., Raynal V., Bohec M., Reyes C., Rapinat A., Helsmoortel C., Jongen L., Hoste G., Neven P., Wildiers H., Smeets A., Nevelsteen Read More

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue 5, Pages 808–823. AUTHORS: Lorenza Mittempergher, Leonie J.M.J. Delahaye, Anke T. Witteveen, Jacob B. Spangler, Fariet Hassenmahomed, Sammy Mee, Soufiane Mahmoudi, Jiang Chen, Simon Bao, Mireille H.J. Snel, Sandra Leidelmeijer, Naomi Besseling, Anne Bergstrom Lucas, Carlos Pabón-Peña, Sabine C. Linn, Read More